Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | COFO and Secretary | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,995 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 2,768 · Balance 278,995 F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026. F2: Includes 135,475 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 523,749 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 523,749 F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.
F2: Includes 135,475 Unvested RSUs.
F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2019 Filed Sep 11, 2019 20:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,500 | $18.16 | $136,200.00 |
DisclosureSEC source: 0001209191-19-049178 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 610,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,975 | $18.60 | $36,730.66 |
DisclosureSEC source: 0001209191-19-047187 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,710 F2 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047187 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,643 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F4 · derivative.exercise_date: 50% of the shares subject to the option vested on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through such date. F4 · derivative.expiration_date: 50% of the shares subject to the option vested on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through such date. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-047187 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 22:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,500 | $18.81 | $141,075.00 |
DisclosureSEC source: 0001209191-19-045394 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 617,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.21 to $19.12 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $20.90 | $8,360.00 |
DisclosureSEC source: 0001209191-19-041710 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 625,089 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.87 to $20.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,100 | $20.25 | $143,775.00 |
DisclosureSEC source: 0001209191-19-041710 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 625,489 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.86 to $20.85 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 22:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,500 | $18.77 | $140,775.00 |
DisclosureSEC source: 0001209191-19-036500 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 632,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.49 to $19.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| May 13, 2019 Filed May 13, 2019 21:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $21.09 | $52,725.00 |
DisclosureSEC source: 0001209191-19-029432 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 640,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.69 to $21.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| May 10, 2019 Filed May 13, 2019 21:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $22.19 | $55,475.00 |
DisclosureSEC source: 0001209191-19-029432 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 642,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.81 to $22.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| May 09, 2019 Filed May 13, 2019 21:52 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $22.86 | $57,150.00 |
DisclosureSEC source: 0001209191-19-029432 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 645,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.45 to $23.44 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| April 11, 2019 Filed Apr 11, 2019 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,512 | $27.73 | $69,657.76 |
DisclosureSEC source: 0001209191-19-024390 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 647,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $27.46 to $28.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| April 10, 2019 Filed Apr 11, 2019 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,513 | $28.26 | $71,017.38 |
DisclosureSEC source: 0001209191-19-024390 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 650,101 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $27.86 to $28.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,475 | $28.17 | $69,720.75 |
DisclosureSEC source: 0001209191-19-024390 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 652,614 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $27.82 to $28.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,512 | $24.33 | $36,786.96 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 655,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.09 to $24.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,000 | $23.60 | $23,600.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 656,601 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.04 to $24.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,513 | $22.40 | $56,291.20 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 657,601 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.01 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 275 | $21.80 | $5,995.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,114 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.79 to $21.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,200 | $21.20 | $46,640.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,389 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.73 to $21.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 23:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,700 | $20.24 | $34,408.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 662,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.11 to $20.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 23:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 800 | $19.73 | $15,784.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 664,289 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.05 to $19.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 23:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,266 | $19.35 | $24,497.10 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 665,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.18 to $19.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 23:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,234 | $18.74 | $23,125.16 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 666,355 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.18 to $19.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 23:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $18.11 | $45,275.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 667,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.26 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001209191-19-009077 · doc4.xml · derivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2029-02-06 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 7, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009077 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 11, 2019 Filed Jan 11, 2019 22:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $20.80 | $52,000.00 |
DisclosureSEC source: 0001209191-19-003443 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 670,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.24 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 22:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $19.99 | $49,975.00 |
DisclosureSEC source: 0001209191-19-003443 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 672,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.44 to $20.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 22:11 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $20.31 | $50,775.00 |
DisclosureSEC source: 0001209191-19-003443 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 675,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.94 to $20.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 12, 2018 Filed Dec 12, 2018 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $20.80 | $52,000.00 |
DisclosureSEC source: 0001209191-18-062266 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 677,589 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.51 to $20.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $20.22 | $50,550.00 |
DisclosureSEC source: 0001209191-18-062266 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 680,089 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.90 to $20.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,500 | $20.18 | $50,450.00 |
DisclosureSEC source: 0001209191-18-062266 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 682,589 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.74 to $20.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,859 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001209191-18-054042 · doc4.xml · derivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,641 Underlying: Common Stock · 5,859 shares Expires 2027-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on August 22, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 1,184 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-18-054042 · doc4.xml · derivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,898 Underlying: Common Stock · 1,184 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,859 | $9.60 | $56,246.40 |
DisclosureSEC source: 0001209191-18-054042 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:58 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 1,184 | $5.28 | $6,251.52 |
DisclosureSEC source: 0001209191-18-054042 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 11,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048030 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,286 Underlying: Common Stock · 11,286 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units shall vest on August 20, 2019 and the remaining 50% shall vest on August 20, 2020, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 5,918 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-18-039531 · doc4.xml · derivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,082 Underlying: Common Stock · 5,918 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,918 | $5.28 | $31,247.04 |
DisclosureSEC source: 0001209191-18-039531 · doc4.xml · nonDerivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:55 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001209191-18-014728 · doc4.xml · derivative · entry 1 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-02-25 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.